- Meridian Bioscience (NASDAQ:VIVO -0.1%) FQ1 results: Revenues: $48M (+7.1%); COGS: $18.8M (+11.9%); R&D Expense: $3.1M (+6.9%); SG&A: $13.5M (-0.4%); Operating Income: $12.7M (+9.5%); Net Income: $7.9M (+6.8%); EPS: $0.19 (+5.6%); Quick Assets: $49.5M (+13.3%).
- 2015 Guidance: Net Revenues: $193M - 200M, EPS: $0.85 - 0.91.